Peptide Vaccination with an Anchor-Replaced CTL Epitope Protects Against Human Papillomavirus Type 16-Induced Tumors Expressing the Wild-Type Epitope
Michel Vierboom(Biomedical Primate Research Centre), W. Martin Kast(University of Southern California), Jan W. Drijfhout(Leiden University), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands)), Jacques Neefjes(Leiden University Medical Center), Jan ter Schegget(Department of Virology), Anne Neisig(QIMR Berghofer Medical Research Institute), Mariet C.W. Feltkamp(Leiden University Medical Center)
Cited by 35
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840